Dynavax’s Vasculitis Case With Heplisav Could Be Random
This article was originally published in The Pink Sheet Daily
Executive Summary
Response to FDA on hepatitis B vaccine clinical hold points to a case in the control as well as the drug arm.
You may also be interested in...
GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease
The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.
GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease
The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.
Heplisav Phase III Data Good, But Timing Of Complete Response Still Unclear
Dynavax, Merck assembling package on HBV drug for FDA.